FormerXBC Inc XEBEQ

RE:Antibe's timeline

[GGreen]

Thanks for your comment on ATE. It will be interesting to see how both respond to uplisting. Actually I would add a third to make it interesting... PYR. All announced uplisting and all in slightly different stages of development / commercialization. Here's how I would categorize them:

XBC - furtherest along in terms of commercialization / growth / revenue. The stock can stand on its own and no reverse split will be required. The fact that they are in a "hot" sectors right now (ie. ESG, RNG, hydrogen etc) , nice revenue ramp, good margins (Q3 dip aside), vertical & multipronged strategy - institutionals will be looking to follow and add to funds / client portfolios. I wouldn't be surprised with another 15-25% share price growth by year-end - assuming no COVID melt-down

PYR - starting up the growth curve with expectation of large contracts to push stock further up (also did financing recently at $3.60 which I have found is usually a catalyst for price appreciation in the 2-5 months post closing BUT I don't like the amount of pumping done by the CEO who happens to own over 50% of the company. He spends more time posting on AGORA.com and issuing PR about contract payments received than closing those large contracts! Governance seems poor, Board needs to be diversified - not sure institutional investors will buy in (at least not the large blue chip ones you can rely on). Also trying to push it as a "Green" play - I don't buy it. I'll ride this one for a while and expect some run up IF deals get signed & delivered (but not simply because of uplisiting).

ATE - probably been kicking the can down the road the longest but hey it's biotech and from having been in a biotech for 12 years (4 as pubco) it's along and lonely road. Going public is often more of a financing event more than anything else. There's a lot of angry (long-term) investors that got really mad at CEO selling on some data earlier in the year that sent the stock to its current levels. Having said that data on lead candidfate looks real strong and in a sizeable market that they could have some significant impact this one has a lot of upside from where it is now BUT with that comes with a lot of risk. They've also done a financing in the past few months. My take is that they are now shopping the data to med-large pharma to see if there are any suitors as they prep for a 2 yr Phase 3 trial. I won't ride it through Ph 3 but I am interested / hopeful that the good data will get therm some partnership deals whether with regional players or a preferred complete takeout. My guess the CEO and legacy insitituionals would be open to a takeout if the price if fair. Some interest from some of the large players could make it interesting. Their uplisting will require a reverse split (likely tomorrow when they start trading on the big board) - eek! Many examples of stocks taking a beating after a reverse split (eg. GPV, ACB). I would have preferred that they uplist after a partnership announcement to get the stock price up before the reverse split. Could it be that they are planning on the big board first and then start rolling out the partnership announcments in the coming months which instituionals could then start to buy. Hmmmm time will tell.

This will keep the coming weeks / months interesting now that the US election (distraction) is a bit more tame.